Tumor Immunotherapy
T Cell Activation and Clonal Selection
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Nov 22, 2025

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Stepan V Podlesnykh1, Kristina E Abramova1, Anastasia Gordeeva1
1Russian-American Anti-Cancer Center, Altai State University, 61 Lenin St., 656049 Barnaul, Russia.
Researchers developed a synthetic peptide, p344, that targets the CTLA-4 immune checkpoint. This peptide shows potential for cancer immunotherapy by blocking CTLA-4 interactions, offering an alternative to monoclonal antibodies.
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: